GBP4 and non-small cell lung carcinoma: GBP4 enhances melanoma immune checkpoint responses, reflecting TME dynamics and aiding anti-EGFR therapy in non-small cell lung cancer, linked to its Golgi and plasma membrane localization [62,63].